McKesson to Pay $151 Million to Settle Drug-Pricing Suit

The upcoming price negotiations are the third cycle since the Inflation Reduction Act was passed in 2022.

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Experts raise concerns that CDC childhood immunization changes could reduce vaccine uptake and weaken trust in public health guidance.

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

CMS’s 2027 proposed MA payment rate increase of .09% falls short of expectations, potentially increasing premiums and reducing benefits for seniors.

With the CDC’s decision to roll back recommendations to vaccinate for several conditions, questions have arisen as to what that may mean in the US.